Indeed, the pan-HER TKi lapatinib prevents ERK rebound and sensitizes BRAF-mutant thyroid cancer cells to RAF or MAPK kinase inhibitors [10]. This evidence concerns the gene BRAF and thyroid gland carcinoma.